SCHEMBL828082

SCHEMBL828082

COc1cnccc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30824501 1.00
SCHEMBL1106628 0.81
SCHEMBL2538708 0.80 CA12 (0.53)
Hydrochloric Acid SCHEMBL29090737 0.79 CA12 (0.48)
SCHEMBL14422873 0.79
SCHEMBL12934590 0.78 CYP1A2 (0.49)
Hydrochloric Acid SCHEMBL27935953 0.78 CA12 (0.52)
SCHEMBL28480029 0.77 CHRNB2 (0.40)
SCHEMBL15596168 0.77 CHRNB2 (0.47)
SCHEMBL9372692 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108822135-B Synthesis method of nitrogen heterocyclic ring substituted thieno [3, 2-d ] thiazole and derivatives thereof 湘潭大学 2021-02-02 CN claimed
CN-108822135-A A kind of synthetic method of the cyclosubstituted thieno of azepine [3,2-d] thiazole and its derivative 湘潭大学 2018-11-16 CN claimed
EP-4727941-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2026-04-22 EP disclosed
WO-2024254834-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-12-19 WO disclosed
WO-2024255885-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-12-19 WO disclosed
WO-2024255164-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-12-19 WO disclosed
US-20240279179-A1 SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2024-08-22 US disclosed
CN-112645866-B Synthesis and application of 1-benzyl-4-methyl-5-alkoxy-1, 2,3, 6-tetrahydropyridine derivative 浙江奥翔药业股份有限公司 2024-03-22 CN disclosed
EP-4269391-A1 SYNTHESIS AND USE OF 1-BENZYL-4-METHYL-5-ALKOXY-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVE Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) 2023-11-01 EP disclosed
CN-114644636-B Method for preparing tofacitinib key intermediate 江苏恒沛药物科技有限公司 2023-10-20 CN disclosed
US-20230312562-A1 TETRAHYDRO-3H-PYRAZOLO QUINOLONE AND TETRAHYDRO-3H-PYRROLO[3,2-F]QUINOLINE -CONTAINING COMPOUNDS AND USES THEREOF PURDUE RESEARCH FOUNDATION (US) 2023-10-05 US disclosed
WO-2007020050-A2 BICYCLIC BISAMIDE DERIVATIVES AND USE THEREOF AS INSECTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2006-05-04 US disclosed
US-20040192752-A1 Anti-HIV pyrazole derivatives DYMOCK BRIAN WILLIAM (GB) 2004-09-30 US disclosed
US-6699887-B2 ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PYRRAZOLE SULFIDE OR ETHER COMPOUND TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION HOFFMANN-LA ROCHE INC. 2004-03-02 US disclosed
EP-1326843-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. Hoffmann-La Roche AG (CH) 2003-07-16 EP disclosed
US-20030018197-A1 Anti-HIV pyrazole derivatives HOFFMANN-LA ROCHE INC. 2003-01-23 US disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
WO-2002030907-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-04-18 WO disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed